What does NDC PHARMA do?

NDC PHARMA is a pharmacy in Hooglede. Public Limited, started on 26 September 1986, 1 establishment.

What is the address of NDC PHARMA?

The registered office of NDC PHARMA is located at Bruggestraat 2, 8830 Hooglede.

Is NDC PHARMA still active?

Yes. According to the CBE (30 October 2026) NDC PHARMA is active, legal situation “Normale toestand”, started on 26 September 1986.

Is NDC PHARMA registered on Peppol?

Yes, NDC PHARMA is registered on the Peppol network with ID 0208:0429465124.

What is the enterprise number of NDC PHARMA?

The enterprise number of NDC PHARMA is BE0429465124.

When was NDC PHARMA founded?

NDC PHARMA was founded on 26 September 1986.

Who are the directors of NDC PHARMA?

According to the 2025 annual accounts, the directors of NDC PHARMA are: Pharma World.

Is NDC PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 26 September 1986; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did NDC PHARMA make in 2025?

NDC PHARMA posted a profit after taxes of € 188,352 in financial year 2025.

What is the revenue of NDC PHARMA?

As a small company, NDC PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 440,846.

How much does an employee at NDC PHARMA earn?

The average wage cost per full-time employee at NDC PHARMA was € 69,500 in 2025: staff costs of € 222,392 for 3.2 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does NDC PHARMA have?

According to the 2025 annual accounts, NDC PHARMA has 3.2 full-time equivalents (FTE).

Does NDC PHARMA have a website?

Yes, NDC PHARMA has a website at pharmaworld.be.

NDC PHARMA (Public Limited) - Hooglede - BE0429465124

Dossier NDC PHARMA, printed on 30 October 2026 from databakkes.be/en/0429465124/ndc-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

NDC PHARMA from Hooglede, company number BE0429465124, closed financial year 2025 with a result of € 188,352 after tax. For that financial year NDC PHARMA recorded a gross margin of € 440,846 and equity of € 234,089. Compared with financial year 2024, the result moved from € 101,503 to € 188,352. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on December 29, 2025.

What it is worth Growing

€ 234,089

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 188,352

▲ 86% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 105,151

▼ 42% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 178,000 paid out

95 % of the profit went to the shareholders, mostly to PHARMA WORLD (99 % of the shares). That is where the money ends up.

People and assets in 2025

Full-time equivalents

3.2

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 222,392

▲ 2% vs 2024

€ 69,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 944

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 17 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 156,397

▼ 5% vs 2024

€ 9,037 is repaid this year. At this pace the long-term loan is gone in ≈ 17 years.

Owed to suppliers

€ 100,362

▲ 35% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 13,613

▼ 42% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 326,746 Gross margin 2022: € 326,746 First fiscal year in the series	€ 340,317 Gross margin 2023: € 340,317 ▲ 4% vs 2022 (€ 326,746) Favourable step	€ 379,505 Gross margin 2024: € 379,505 ▲ 12% vs 2023 (€ 340,317) Favourable step	€ 440,846 Gross margin 2025: € 440,846 ▲ 16% vs 2024 (€ 379,505) Favourable step	▲ 16%
Profit after taxes	€ 153,347 Profit after taxes 2022: € 153,347 First fiscal year in the series	€ 121,399 Profit after taxes 2023: € 121,399 ▼ 21% vs 2022 (€ 153,347) Unfavourable step	€ 101,503 Profit after taxes 2024: € 101,503 ▼ 16% vs 2023 (€ 121,399) Unfavourable step	€ 188,352 Profit after taxes 2025: € 188,352 ▲ 86% vs 2024 (€ 101,503) Favourable step	▲ 86%
Equity	€ 232,698 Equity 2022: € 232,698 First fiscal year in the series	€ 232,788 Equity 2023: € 232,788 Unchanged (€ 232,698) Favourable step	€ 233,385 Equity 2024: € 233,385 Unchanged (€ 232,788) Favourable step	€ 234,089 Equity 2025: € 234,089 Unchanged (€ 233,385) Favourable step
Total debts	€ 328,652 Total debts 2022: € 328,652 First fiscal year in the series	€ 309,743 Total debts 2023: € 309,743 ▼ 6% vs 2022 (€ 328,652) Favourable step	€ 535,119 Total debts 2024: € 535,119 ▲ 73% vs 2023 (€ 309,743) Unfavourable step	€ 538,803 Total debts 2025: € 538,803 ▲ 1% vs 2024 (€ 535,119) Unfavourable step	▲ 1%
Cash	€ 66,370 Cash 2022: € 66,370 First fiscal year in the series	€ 132,952 Cash 2023: € 132,952 ▲ 100% vs 2022 (€ 66,370) Favourable step	€ 180,665 Cash 2024: € 180,665 ▲ 36% vs 2023 (€ 132,952) Favourable step	€ 105,151 Cash 2025: € 105,151 ▼ 42% vs 2024 (€ 180,665) Unfavourable step	▼ 42%
Land & buildings	-	-	€ 212,270 Land & buildings 2024: € 212,270 First fiscal year in the series	€ 201,320 Land & buildings 2025: € 201,320 ▼ 5% vs 2024 (€ 212,270) Unchanged	▼ 5%
Retained profit	€ 162,698 Retained profit 2022: € 162,698 First fiscal year in the series	€ 162,788 Retained profit 2023: € 162,788 Unchanged (€ 162,698) Favourable step	€ 163,385 Retained profit 2024: € 163,385 Unchanged (€ 162,788) Favourable step	€ 164,089 Retained profit 2025: € 164,089 Unchanged (€ 163,385) Favourable step
Dividend	€ 172,000 Dividend 2022: € 172,000 First fiscal year in the series	€ 115,000 Dividend 2023: € 115,000 ▼ 33% vs 2022 (€ 172,000) Unchanged	€ 92,000 Dividend 2024: € 92,000 ▼ 20% vs 2023 (€ 115,000) Unchanged	€ 178,000 Dividend 2025: € 178,000 ▲ 93% vs 2024 (€ 92,000) Unchanged	▲ 93%
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 0 Bank debt 2023: € 0 Unchanged (€ 0) Unchanged	€ 165,086 Bank debt 2024: € 165,086 Unchanged (€ 0) Unfavourable step	€ 156,397 Bank debt 2025: € 156,397 ▼ 5% vs 2024 (€ 165,086) Favourable step	▼ 5%
Balance sheet total	€ 561,350 Balance sheet total 2022: € 561,350 First fiscal year in the series	€ 542,531 Balance sheet total 2023: € 542,531 ▼ 3% vs 2022 (€ 561,350) Unchanged	€ 768,504 Balance sheet total 2024: € 768,504 ▲ 42% vs 2023 (€ 542,531) Unchanged	€ 772,892 Balance sheet total 2025: € 772,892 ▲ 1% vs 2024 (€ 768,504) Unchanged	▲ 1%
Employees (FTE)	3.2 Employees (FTE) 2022: 3.2 First fiscal year in the series	3.2 Employees (FTE) 2023: 3.2 Unchanged (3.2) Unchanged	3.2 Employees (FTE) 2024: 3.2 Unchanged (3.2) Unchanged	3.2 Employees (FTE) 2025: 3.2 Unchanged (3.2) Unchanged

Key figures of NDC PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.

What happened to NDC PHARMA?

What happened at NDC PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Dec 29, 2025 New annual accounts for financial year 2025: profit of € 188,352 (▲ 86% vs 2024). Source: NBB ↗
2005 Pharma World became a director. NBB
Nov 10, 1986 New establishment in Hooglede. KBO
Sep 26, 1986 Start of the company according to the CBE. KBO

In short

From € 153,347 profit in 2022 to € 188,352 profit in 2025.

Paid € 18,144 in corporate taxes since 2022.

Best year ever: 2025, with € 188,352 profit.

On average € 137,800 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

PHARMA WORLD 99.3%

The stake of PHARMA WORLD comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

NDC PHARMA

Behind NDC PHARMA is Pharma World. The shares are held by PHARMA WORLD (99.3%).

Directors

According to the 2025 annual accounts

Pharma World

Director · represented by Decloedt NELE

since 2005

Shareholders

PHARMA WORLD

99.3%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Bruggestraat 2

8830 Hooglede

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

Vereniging van mede-eigenaars Residentie Gulden Sporen E te Hooglede, Bruggestraat 2

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTP pharmaworld.be

Technologies

ApacheBootstrapCookie ConsentGoogle AnalyticsGoogle FontsVue.jsjQueryjsDelivrreCAPTCHA

Hosting & Email

Email provider

Microsoft 365

Hosting

DIGICERT - Tiggee LLC, US

Website info

HTTPS Nee

Languages NL

Features

Blog Contact page

Security

✗ HTTPS

✓ SPF

✗ DMARC

Network

✓ Load balancing

Details

Company number

0429.465.124

VAT number

BE 0429.465.124

Registered office

Bruggestraat 2, 8830 Hooglede

Names & denominations

NDC PHARMA

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

26 September 1986

Peppol

Active · Active since 17 Mar 2025

Contact

pharmaworld.be

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

NDC PHARMA

Financials

What happened to NDC PHARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Website

Technologies

Hosting & Email

Website info

Features

Security

Network

Details

Frequently asked questions